New obesity drug boosts GLP-1 weight loss without added side effects A new class of weight-loss drug has shown it can significantly boost weight loss when paired with GLP-1 therapy without adding side effects in a mid-stage clinical trial, pointing to a powerful new combination approach to tackling obesity
Studies on ipamorelins effects on postoperative ileus (POI) reveal potential benefits in improving gastric motility
Consequences of the -ketoglutarate dehydrogenase inhibition for neuronal metabolism and survival: implications for neurodegenerative diseases
L-karnitin ya asitlerinin mitokondriye tanmasna yardmc olarak ene
PLoS ONE 8 , e78919 (2013)
Darbalaei S, Yuliantie E, Dai A, Chang R, Zhao P, Yang D, et al